CRK16 Antibody
Description
Potential Target 1: CK16 (Keratin 16) Antibodies
CK16 (Keratin 16), encoded by the KRT16 gene, is a 473-amino acid protein involved in cytoskeletal organization and epithelial integrity. Anti-CK16 antibodies are primarily used in research applications such as immunohistochemistry (IHC), Western blot (WB), and ELISA to study conditions like psoriasis, wound healing, and corneal epithelial disorders .
Potential Target 2: Crk Antibodies
Crk (CT10 regulator of kinase) is an adaptor protein encoded by the CRK gene, involved in signal transduction pathways regulating cell motility and apoptosis. Anti-Crk antibodies (e.g., MAB4316, MA5-15891) are used to study oncogenic transformations and immune cell interactions .
Research Findings for Crk Antibodies
-
Functional Roles:
-
Therapeutic Relevance:
Antibody Performance Data
| Product Code | Clone | Applications Validated | Species Reactivity |
|---|---|---|---|
| MAB4316 | 463414 | WB, ELISA | Human, Mouse |
| MA5-15891 | 3G11C1 | WB, IHC, FACS | Human |
Analysis of Nomenclature Ambiguity
The term "CRK16" may conflate:
-
CK16 (Keratin 16), a structural protein.
-
Crk (UniProt: P46108), a signaling adaptor.
-
MRK16, an anti-P-glycoprotein monoclonal antibody used in cancer immunotherapy .
Validation and Quality Control
Recent studies emphasize the importance of antibody validation using knockout (KO) controls. For example:
A 2023 meta-analysis found that ~50% of commercial antibodies fail target recognition in common assays, underscoring the need for rigorous validation .
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
KEGG: ath:AT4G23240
STRING: 3702.AT4G23240.1
Q&A
Here’s a structured FAQ collection for CRK16 (CD16a) antibody research, organized by scientific depth and methodological focus, based on current academic literature and experimental best practices:
Advanced Research Questions
How to resolve contradictory data in CD16a epitope mapping studies?
-
Troubleshooting framework:
What computational approaches optimize CD16a bispecific engagers for solid tumor penetration?
How to mitigate interference from soluble CD16a in serum during functional assays?
-
Technical solutions:
Methodological Considerations
What in vitro models best recapitulate CD16a polymorphism effects?
-
Model system comparison:
Model Advantages Limitations Primary NK donors (V/F allotypes) Physiological relevance Inter-donor variability CD16a-KO THP-1 + transfection Controlled expression Monocytic lineage bias Humanized NSG mice In vivo functionality High cost, technical complexity
How to quantify ADCC enhancement while controlling for NK cell exhaustion?
-
Multiparametric assay design:
Validation & Reproducibility
What criteria establish lot-to-lot consistency in CD16a antibody production?
-
QC parameters:
